Jaguar Health's Ethnobotanical Research Advances Crofelemer Development

Jaguar Health is moving forward with the development of their FDA-approved botanical drug, Crofelemer, for intestinal failure disorders like microvillus inclusion disease (MVID) and short bowel syndrome (SBS). Derived from the Croton lechleri tree, Crofelemer aims to become the first oral adjunctive therapy for these conditions.

This development stems from collaborations with indigenous experts and sustainable harvesting practices in Peru. These efforts have emphasized the importance of integrating traditional botanical knowledge with modern pharmacology. Jaguar Health's approach represents a unique pathway in drug development, highlighting ethnobotanical research and sustainable sourcing as core strategies.

Crofelemer's anti-secretory mechanism may reduce the need for parenteral support (PS) in rare GI disorders. The company's ongoing trials and upcoming presentations underscore its commitment to addressing unmet medical needs in genetically defined rare disorders.